Measured - real values of intraocular tension, 24 h after the application of brolucizumab intravitreal injection in patients with wAMD

Hajdari, Arsim and Velickova, Nevenka (2024) Measured - real values of intraocular tension, 24 h after the application of brolucizumab intravitreal injection in patients with wAMD. MEDIS – International Journal of Medical Sciences and Research, 3 (3). pp. 23-26. ISSN 2671-3497 (Online)

Text MEASURED+-+REAL+VALUES+OF+INTRAOCULAR+TENSION,+24+H+AFTER+THE+APPLICATION+OF+BROLUCIZUMAB+INTRAVITREAL+INJECTION+IN+PATIENTS+WITH+wAMD.pdf Download (238kB)

Abstract

Intraocular tension (OHT) refers to any situation in which the intraocular pressure (IOP) is greater than 21 mm Hg in one or both eyes, measured with a non-contact tonometer on 2 or more occasions. To present the real values of intraocular tension 24h after the application of Brolucizumab intravitreal injection of wAMD (wet Age-related macular degeneration) in the age over 50 years. Screening examination of patients for intraocular tension was done between 2023 and 2024 at the Italian Eye Hospital in Pristina 24h after the application of Brolucizumab wAMD intravitreal injection. Results: A total of 100 patients participated in the studies, 36 women and 64 men over 50 years old. After measuring intraocular pressure (IOP), only 10 patients had IOP values of 21mmHg or 10%, where most were male, 6% and 4% were female, and age. most of them were over 60 years old, only in one case the age was 56 years. Conclusions: Management of patients with intraocular pressure risk a global risk that plays a vital role despite all the unreliable data considering patients, status, life expectancy and personal preferences. Looking at our tension is presented in the intraocular in the number of patients passed after the application of wAMD is the last considering also the age of patients over 60 years 99% and only 1% 56 years. We can a clear relationship between intraocular tension and the establishment of the application of Brolucizumab intravitreal injection in patients with wAMD with a real reduction in the incidence of blindness from wAMD, which has a cost to the health care system. However, there is mixed evidence on the impact of anti-VEGF on other patient-related outcomes.

Item Type:	Article
Subjects:	Medical and Health Sciences > Basic medicine Medical and Health Sciences > Clinical medicine
Divisions:	Faculty of Medical Science
Depositing User:	Nevenka Velickova
Date Deposited:	01 Oct 2024 08:17
Last Modified:	01 Oct 2024 08:17
URI:	https://eprints.ugd.edu.mk/id/eprint/34764

Actions (login required)

View Item